Search

Your search keyword '"Glasspool, Rosalind M"' showing total 189 results
Start Over Author "Glasspool, Rosalind M"
189 results on '"Glasspool, Rosalind M"'

1. Survival and modelled cancer antigen-125 ELIMination rate constant K score in ovarian cancer patients in first-line before poly(ADP-ribose) polymerase inhibitor era: A Gynaecologic Cancer Intergroup meta-analysis

Author

Corbaux, Pauline, You, Benoit, Glasspool, Rosalind M., Yanaihara, Nozomu, Tinker, Anna V., Lindemann, Kristina, Ray-Coquard, Isabelle L., Mirza, Mansoor R., Subtil, Fabien, Colomban, Olivier, Péron, Julien, Karamouza, Eleni, McNeish, Iain, Kelly, Caroline, Kagimura, Tatsuo, Welch, Stephen, Lewsley, Liz-Anne, Paoletti, Xavier, and Cook, Adrian

Published
2023
Full Text
View/download PDF

3. Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk

Author

Yang, Yaohua, Wu, Lang, Shu, Xiang, Lu, Yingchang, Shu, Xiao-Ou, Cai, Qiuyin, Beeghly-Fadiel, Alicia, Li, Bingshan, Ye, Fei, Berchuck, Andrew, Anton-Culver, Hoda, Banerjee, Susana, Benitez, Javier, Bjørge, Line, Brenton, James D, Butzow, Ralf, Campbell, Ian G, Chang-Claude, Jenny, Chen, Kexin, Cook, Linda S, Cramer, Daniel W, deFazio, Anna, Dennis, Joe, Doherty, Jennifer A, Dörk, Thilo, Eccles, Diana M, Edwards, Digna Velez, Fasching, Peter A, Fortner, Renée T, Gayther, Simon A, Giles, Graham G, Glasspool, Rosalind M, Goode, Ellen L, Goodman, Marc T, Gronwald, Jacek, Harris, Holly R, Heitz, Florian, Hildebrandt, Michelle A, Høgdall, Estrid, Høgdall, Claus K, Huntsman, David G, Kar, Siddhartha P, Karlan, Beth Y, Kelemen, Linda E, Kiemeney, Lambertus A, Kjaer, Susanne K, Koushik, Anita, Lambrechts, Diether, Le, Nhu D, Levine, Douglas A, Massuger, Leon F, Matsuo, Keitaro, May, Taymaa, McNeish, Iain A, Menon, Usha, Modugno, Francesmary, Monteiro, Alvaro N, Moorman, Patricia G, Moysich, Kirsten B, Ness, Roberta B, Nevanlinna, Heli, Olsson, Håkan, Onland-Moret, N Charlotte, Park, Sue K, Paul, James, Pearce, Celeste L, Pejovic, Tanja, Phelan, Catherine M, Pike, Malcolm C, Ramus, Susan J, Riboli, Elio, Rodriguez-Antona, Cristina, Romieu, Isabelle, Sandler, Dale P, Schildkraut, Joellen M, Setiawan, Veronica W, Shan, Kang, Siddiqui, Nadeem, Sieh, Weiva, Stampfer, Meir J, Sutphen, Rebecca, Swerdlow, Anthony J, Szafron, Lukasz M, Teo, Soo Hwang, Tworoger, Shelley S, Tyrer, Jonathan P, Webb, Penelope M, Wentzensen, Nicolas, White, Emily, Willett, Walter C, Wolk, Alicja, Woo, Yin Ling, Wu, Anna H, Yan, Li, Yannoukakos, Drakoulis, Chenevix-Trench, Georgia, Sellers, Thomas A, Pharoah, Paul DP, Zheng, Wei, and Long, Jirong

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Genetics, Biotechnology, Rare Diseases, Ovarian Cancer, Cancer Genomics, Prevention, Women's Health, Cancer, Clinical Research, Human Genome, 2.1 Biological and endogenous factors, Biomarkers, Tumor, Carcinoma, Ovarian Epithelial, Cohort Studies, DNA Methylation, Female, Genetic Predisposition to Disease, Humans, Models, Genetic, Ovarian Neoplasms, Predictive Value of Tests, Risk, White People, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

DNA methylation is instrumental for gene regulation. Global changes in the epigenetic landscape have been recognized as a hallmark of cancer. However, the role of DNA methylation in epithelial ovarian cancer (EOC) remains unclear. In this study, high-density genetic and DNA methylation data in white blood cells from the Framingham Heart Study (N = 1,595) were used to build genetic models to predict DNA methylation levels. These prediction models were then applied to the summary statistics of a genome-wide association study (GWAS) of ovarian cancer including 22,406 EOC cases and 40,941 controls to investigate genetically predicted DNA methylation levels in association with EOC risk. Among 62,938 CpG sites investigated, genetically predicted methylation levels at 89 CpG were significantly associated with EOC risk at a Bonferroni-corrected threshold of P < 7.94 × 10-7. Of them, 87 were located at GWAS-identified EOC susceptibility regions and two resided in a genomic region not previously reported to be associated with EOC risk. Integrative analyses of genetic, methylation, and gene expression data identified consistent directions of associations across 12 CpG, five genes, and EOC risk, suggesting that methylation at these 12 CpG may influence EOC risk by regulating expression of these five genes, namely MAPT, HOXB3, ABHD8, ARHGAP27, and SKAP1. We identified novel DNA methylation markers associated with EOC risk and propose that methylation at multiple CpG may affect EOC risk via regulation of gene expression. SIGNIFICANCE: Identification of novel DNA methylation markers associated with EOC risk suggests that methylation at multiple CpG may affect EOC risk through regulation of gene expression.

Published
2019

4. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment (ICON8): overall survival results from an open-label, randomised, controlled, phase 3 trial

Author

Clamp, Andrew R, James, Elizabeth C, McNeish, Iain A, Dean, Andrew, Kim, Jae-Won, O'Donnell, Dearbhaile M, Gallardo-Rincon, Dolores, Blagden, Sarah, Brenton, James, Perren, Tim J, Sundar, Sudha, Lord, Rosemary, Dark, Graham, Hall, Marcia, Banerjee, Susana, Glasspool, Rosalind M, Hanna, C Louise, Williams, Sarah, Scatchard, Kate M, Nam, Helena, Essapen, Sharadah, Parkinson, Christine, McAvan, Lucy, Swart, Ann Marie, Popoola, Babasola, Schiavone, Francesca, Badrock, Jonathan, Fananapazir, Fuad, Cook, Adrian D, Parmar, Mahesh, Kaplan, Richard, and Ledermann, Jonathan A

Published
2022
Full Text
View/download PDF

5. Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee

Author

Kurtz, Jean-Emmanuel, Gebski, Val, Sukhin, Vladyslav, Carey, Mark, Kong, Iwa, Glasspool, Rosalind M., Berek, Jonathan S., de Paiva Batista, Mariana, Hall, Marcia, Kim, Jae-Weon, Yeoshoua, Effi, Fujiwara, Noriko, Nam, Byung-Ho, Polleis, Sandra, Lee, Jung-Yun, Strojna, Aleksandra, Farrelly, Laura, Schwameis, Richard, Fossati, Roldano, Darlington, Anne-Sophie, Lai, Chyong-Huey, Wright, Alexi A., Rosenblat, Orgad, Harter, Phillip, Roxburgh, Patricia, Chowdhury, Rahul Roy, Chang, Ting-Chang, Paoletti, Xavier, and Friedlander, Michael

Published
2021
Full Text
View/download PDF

6. Objective responses to first-line neoadjuvant carboplatin–paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial

Author

Morgan, Robert D, McNeish, Iain A, Cook, Adrian D, James, Elizabeth C, Lord, Rosemary, Dark, Graham, Glasspool, Rosalind M, Krell, Jonathan, Parkinson, Christine, Poole, Christopher J, Hall, Marcia, Gallardo-Rincón, Dolores, Lockley, Michelle, Essapen, Sharadah, Summers, Jeff, Anand, Anjana, Zachariah, Abel, Williams, Sarah, Jones, Rachel, Scatchard, Kate, Walther, Axel, Kim, Jae-Weon, Sundar, Sudha, Jayson, Gordon C, Ledermann, Jonathan A, and Clamp, Andrew R

Published
2021
Full Text
View/download PDF

7. No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival

Author

Sucheston-Campbell, Lara E, Cannioto, Rikki, Clay, Alyssa I, Etter, John Lewis, Eng, Kevin H, Liu, Song, Battaglia, Sebastiano, Hu, Qiang, Szender, J Brian, Minlikeeva, Albina, Joseph, Janine M, Mayor, Paul, Abrams, Scott I, Segal, Brahm H, Wallace, Paul K, Soh, Kah Teong, Zsiros, Emese, Anton-Culver, Hoda, Bandera, Elisa V, Beckmann, Matthias W, Berchuck, Andrew, Bjorge, Line, Bruegl, Amanda, Campbell, Ian G, Campbell, Shawn Patrice, Chenevix-Trench, Georgia, Study, on behalf of the Australian Ovarian Cancer, Cramer, Daniel W, Dansonka-Mieszkowska, Agnieszka, Dao, Fanny, Diergaarde, Brenda, Doerk, Thilo, Doherty, Jennifer A, du Bois, Andreas, Eccles, Diana, Engelholm, Svend Aage, Fasching, Peter A, Gayther, Simon A, Gentry-Maharaj, Aleksandra, Glasspool, Rosalind M, Goodman, Marc T, Gronwald, Jacek, Harter, Philipp, Hein, Alexander, Heitz, Florian, Hillemmanns, Peter, Høgdall, Claus, Høgdall, Estrid VS, Huzarski, Tomasz, Jensen, Allan, Johnatty, Sharon E, Jung, Audrey, Karlan, Beth Y, Klapdor, Reudiger, Kluz, Tomasz, Konopka, Bożena, Kjær, Susanne Krüger, Kupryjanczyk, Jolanta, Lambrechts, Diether, Lester, Jenny, Lubiński, Jan, Levine, Douglas A, Lundvall, Lene, McGuire, Valerie, McNeish, Iain A, Menon, Usha, Modugno, Francesmary, Ness, Roberta B, Orsulic, Sandra, Paul, James, Pearce, Celeste Leigh, Pejovic, Tanja, Pharoah, Paul, Ramus, Susan J, Rothstein, Joseph, Rossing, Mary Anne, Rübner, Matthias, Schildkraut, Joellen M, Schmalfeldt, Barbara, Schwaab, Ira, Siddiqui, Nadeem, Sieh, Weiva, Sobiczewski, Piotr, Song, Honglin, Terry, Kathryn L, Van Nieuwenhuysen, Els, Vanderstichele, Adriaan, Vergote, Ignace, Walsh, Christine S, Webb, Penelope M, Wentzensen, Nicolas, Whittemore, Alice S, Wu, Anna H, Ziogas, Argyrios, Odunsi, Kunle, Chang-Claude, Jenny, Goode, Ellen L, and Moysich, Kirsten B

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Clinical Research, Cancer, Ovarian Cancer, Rare Diseases, Prevention, Genetics, Genetic Testing, 2.1 Biological and endogenous factors, Aetiology, Carcinoma, Ovarian Epithelial, Female, Genetic Association Studies, Genetic Variation, Humans, Myeloid-Derived Suppressor Cells, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Australian Ovarian Cancer Study, Medical and Health Sciences, Epidemiology, Biomedical and clinical sciences, Health sciences
Abstract

Background: The precise mechanism by which the immune system is adversely affected in cancer patients remains poorly understood, but the accumulation of immunosuppressive/protumorigenic myeloid-derived suppressor cells (MDSCs) is thought to be a prominent mechanism contributing to immunologic tolerance of malignant cells in epithelial ovarian cancer (EOC). To this end, we hypothesized genetic variation in MDSC pathway genes would be associated with survival after EOC diagnoses.Methods: We measured the hazard of death due to EOC within 10 years of diagnosis, overall and by invasive subtype, attributable to SNPs in 24 genes relevant in the MDSC pathway in 10,751 women diagnosed with invasive EOC. Versatile Gene-based Association Study and the admixture likelihood method were used to test gene and pathway associations with survival.Results: We did not identify individual SNPs that were significantly associated with survival after correction for multiple testing (P < 3.5 × 10-5), nor did we identify significant associations between the MDSC pathway overall, or the 24 individual genes and EOC survival.Conclusions: In this well-powered analysis, we observed no evidence that inherited variations in MDSC-associated SNPs, individual genes, or the collective genetic pathway contributed to EOC survival outcomes.Impact: Common inherited variation in genes relevant to MDSCs was not associated with survival in women diagnosed with invasive EOC. Cancer Epidemiol Biomarkers Prev; 26(3); 420-4. ©2016 AACR.

Published
2017

8. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

Author

Aggarwal, Simi, Bronger, Holger, Brown, Elizabeth B., Buck, Martin, Bukhari, Syed A., Coghlan, Edwina, Cope, Nichola, de Almeida, Michelle Samora, De Kroon, Cornelius D., Dean, Andrew, Devlin, Michael-John, Ditzel, Helena M., Drecoll, Enken, Ebata, Takahiro, Fagotti, Anna, Faruqi, Asma, Feeney, Laura, Gupta, Kavita, Harley, Ian, Inzani, Frediano, Jeyarajah, Arjun R., Koay, M.H. Eleanor, Kroep, Judith R., Lee, Jung-Yun, Leung, Yee, Lockley, Michelle, Loft, Alice R., MaGee, Daniel, Manchanda, Ranjit, McKenna, Sarah, Midha, Divya, Millan, David, Millar, Joanne, Miller, Rowan, Mohan, Ganendra R., Mughal, Sohail, Mukhopadhyay, Asima, Nicolau, Sergio Mancini, Nevin, James, Oakley, Abigail S., Quigley, Mary, Rai, Bhavana, Rajwanshi, Arvind, Salfinger, Stuart G., Scambia, Giovanni, Scatchard, Kate, Schmalfeldt, Barbara, Simcock, Bryony, Singh, Priya, Strickland, Kyle C., Suri, Vainta, Syed, Sheeba, Sykes, Peter, Tamura, Kenji, Tan, Adeline, Tan, Jason, Thompson, Emily, Tinker, Anna V., Trevisan, Georgia, Uyeda, Maria Gabriela Baumgarten Kuster, Vaughan, Michelle M., Weichert, Wilko, Williams, Anthony, Williams, Sarah, Yoshida, Hiroshi, Zorzato, Pier Carlo, Cohen, Paul A., Powell, Aime, Böhm, Steffen, Gilks, C. Blake, Stewart, Colin J.R., Meniawy, Tarek M., Bulsara, Max, Avril, Stefanie, Brockbank, Eleanor C., Bosse, Tjalling, de Azevedo Focchi, Gustavo Rubino, Ganesan, Raji, Glasspool, Rosalind M., Howitt, Brooke E., Kim, Hyun-Soo, Le, Nhu D., Mandalia, Trupti, McCluggage, W. Glenn, McNeish, Iain, Srinivasan, Radhika, Tan, Yun Yi, van der Griend, Rachael, Yunokawa, Mayu, Zannoni, Gian F., and Singh, Naveena

Published
2019
Full Text
View/download PDF

9. Supplementary Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin

Author

Ho, Gwo Yaw, primary, Kyran, Elizabeth L., primary, Bedo, Justin, primary, Wakefield, Matthew J., primary, Ennis, Darren P., primary, Mirza, Hasan B., primary, Vandenberg, Cassandra J., primary, Lieschke, Elizabeth, primary, Farrell, Andrew, primary, Hadla, Anthony, primary, Lim, Ratana, primary, Dall, Genevieve, primary, Vince, James E., primary, Chua, Ngee Kiat, primary, Kondrashova, Olga, primary, Upstill-Goddard, Rosanna, primary, Bailey, Ulla-Maja, primary, Dowson, Suzanne, primary, Roxburgh, Patricia, primary, Glasspool, Rosalind M., primary, Bryson, Gareth, primary, Biankin, Andrew V., primary, Cooke, Susanna L., primary, Ratnayake, Gayanie, primary, McNally, Orla, primary, Traficante, Nadia, primary, DeFazio, Anna, primary, Weroha, S. John, primary, Bowtell, David D., primary, McNeish, Iain A., primary, Papenfuss, Anthony T., primary, Scott, Clare L., primary, and Barker, Holly E., primary

Published
2023
Full Text
View/download PDF

10. Data from Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin

Author

Ho, Gwo Yaw, primary, Kyran, Elizabeth L., primary, Bedo, Justin, primary, Wakefield, Matthew J., primary, Ennis, Darren P., primary, Mirza, Hasan B., primary, Vandenberg, Cassandra J., primary, Lieschke, Elizabeth, primary, Farrell, Andrew, primary, Hadla, Anthony, primary, Lim, Ratana, primary, Dall, Genevieve, primary, Vince, James E., primary, Chua, Ngee Kiat, primary, Kondrashova, Olga, primary, Upstill-Goddard, Rosanna, primary, Bailey, Ulla-Maja, primary, Dowson, Suzanne, primary, Roxburgh, Patricia, primary, Glasspool, Rosalind M., primary, Bryson, Gareth, primary, Biankin, Andrew V., primary, Cooke, Susanna L., primary, Ratnayake, Gayanie, primary, McNally, Orla, primary, Traficante, Nadia, primary, DeFazio, Anna, primary, Weroha, S. John, primary, Bowtell, David D., primary, McNeish, Iain A., primary, Papenfuss, Anthony T., primary, Scott, Clare L., primary, and Barker, Holly E., primary

Published
2023
Full Text
View/download PDF

11. Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31

Author

Permuth-Wey, Jennifer, Lawrenson, Kate, Shen, Howard C, Velkova, Aneliya, Tyrer, Jonathan P, Chen, Zhihua, Lin, Hui-Yi, Ann Chen, Y, Tsai, Ya-Yu, Qu, Xiaotao, Ramus, Susan J, Karevan, Rod, Lee, Janet, Lee, Nathan, Larson, Melissa C, Aben, Katja K, Anton-Culver, Hoda, Antonenkova, Natalia, Antoniou, Antonis C, Armasu, Sebastian M, Bacot, François, Baglietto, Laura, Bandera, Elisa V, Barnholtz-Sloan, Jill, Beckmann, Matthias W, Birrer, Michael J, Bloom, Greg, Bogdanova, Natalia, Brinton, Louise A, Brooks-Wilson, Angela, Brown, Robert, Butzow, Ralf, Cai, Qiuyin, Campbell, Ian, Chang-Claude, Jenny, Chanock, Stephen, Chenevix-Trench, Georgia, Cheng, Jin Q, Cicek, Mine S, Coetzee, Gerhard A, Cook, Linda S, Couch, Fergus J, Cramer, Daniel W, Cunningham, Julie M, Dansonka-Mieszkowska, Agnieszka, Despierre, Evelyn, Doherty, Jennifer A, Dörk, Thilo, du Bois, Andreas, Dürst, Matthias, Easton, Douglas F, Eccles, Diana, Edwards, Robert, Ekici, Arif B, Fasching, Peter A, Fenstermacher, David A, Flanagan, James M, Garcia-Closas, Montserrat, Gentry-Maharaj, Aleksandra, Giles, Graham G, Glasspool, Rosalind M, Gonzalez-Bosquet, Jesus, Goodman, Marc T, Gore, Martin, Górski, Bohdan, Gronwald, Jacek, Hall, Per, Halle, Mari K, Harter, Philipp, Heitz, Florian, Hillemanns, Peter, Hoatlin, Maureen, Høgdall, Claus K, Høgdall, Estrid, Hosono, Satoyo, Jakubowska, Anna, Jensen, Allan, Jim, Heather, Kalli, Kimberly R, Karlan, Beth Y, Kaye, Stanley B, Kelemen, Linda E, Kiemeney, Lambertus A, Kikkawa, Fumitaka, Konecny, Gottfried E, Krakstad, Camilla, Krüger Kjaer, Susanne, Kupryjanczyk, Jolanta, Lambrechts, Diether, Lambrechts, Sandrina, Lancaster, Johnathan M, Le, Nhu D, Leminen, Arto, Levine, Douglas A, Liang, Dong, Kiong Lim, Boon, Lin, Jie, Lissowska, Jolanta, Lu, Karen H, and Lubiński, Jan

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Rare Diseases, Biotechnology, Ovarian Cancer, Cancer, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Carcinoma, Ovarian Epithelial, Chromosomes, Human, Pair 17, Female, Genetic Predisposition to Disease, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Polymorphism, Single Nucleotide, Australian Cancer Study, Australian Ovarian Cancer Study, Consortium of Investigators of Modifiers of BRCA1/2
Abstract

Epithelial ovarian cancer (EOC) has a heritable component that remains to be fully characterized. Most identified common susceptibility variants lie in non-protein-coding sequences. We hypothesized that variants in the 3' untranslated region at putative microRNA (miRNA)-binding sites represent functional targets that influence EOC susceptibility. Here, we evaluate the association between 767 miRNA-related single-nucleotide polymorphisms (miRSNPs) and EOC risk in 18,174 EOC cases and 26,134 controls from 43 studies genotyped through the Collaborative Oncological Gene-environment Study. We identify several miRSNPs associated with invasive serous EOC risk (odds ratio=1.12, P=10(-8)) mapping to an inversion polymorphism at 17q21.31. Additional genotyping of non-miRSNPs at 17q21.31 reveals stronger signals outside the inversion (P=10(-10)). Variation at 17q21.31 is associated with neurological diseases, and our collaboration is the first to report an association with EOC susceptibility. An integrated molecular analysis in this region provides evidence for ARHGAP27 and PLEKHM1 as candidate EOC susceptibility genes.

Published
2013

12. Efficacy and Safety of Weekly Paclitaxel Plus Vistusertib vs Paclitaxel Alone in Patients With Platinum-Resistant Ovarian High-Grade Serous Carcinoma

Author

Banerjee, Susana, primary, Giannone, Gaia, additional, Clamp, Andrew R., additional, Ennis, Darren P., additional, Glasspool, Rosalind M., additional, Herbertson, Rebecca, additional, Krell, Jonathan, additional, Riisnaes, Ruth, additional, Mirza, Hasan B., additional, Cheng, Zhao, additional, McDermott, Jacqueline, additional, Green, Clare, additional, Kristeleit, Rebecca S., additional, George, Angela, additional, Gourley, Charlie, additional, Lewsley, Liz-Anne, additional, Rai, Debbie, additional, Banerji, Udai, additional, Hinsley, Samantha, additional, and McNeish, Iain A., additional

Published
2023
Full Text
View/download PDF

17. Copy number signatures and mutational processes in ovarian carcinoma

Author

Macintyre, Geoff, Goranova, Teodora E., De Silva, Dilrini, Ennis, Darren, Piskorz, Anna M., Eldridge, Matthew, Sie, Daoud, Lewsley, Liz-Anne, Hanif, Aishah, Wilson, Cheryl, Dowson, Suzanne, Glasspool, Rosalind M., Lockley, Michelle, Brockbank, Elly, Montes, Ana, Walther, Axel, Sundar, Sudha, Edmondson, Richard, Hall, Geoff D., Clamp, Andrew, Gourley, Charlie, Hall, Marcia, Fotopoulou, Christina, Gabra, Hani, Paul, James, Supernat, Anna, Millan, David, Hoyle, Aoisha, Bryson, Gareth, Nourse, Craig, Mincarelli, Laura, Sanchez, Luis Navarro, Ylstra, Bauke, Jimenez-Linan, Mercedes, Moore, Luiza, Hofmann, Oliver, Markowetz, Florian, McNeish, Iain A., and Brenton, James D.

Published
2018
Full Text
View/download PDF

18. Table S7 from The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma

Author

Cooke, Susanna L., primary, Ennis, Darren, primary, Evers, Lisa, primary, Dowson, Suzanne, primary, Chan, Mei Yen, primary, Paul, James, primary, Hirschowitz, Lynn, primary, Glasspool, Rosalind M., primary, Singh, Naveena, primary, Bell, Sarah, primary, Day, Elizabeth, primary, Kochman, Agata, primary, Wilkinson, Nafisa, primary, Beer, Philip, primary, Martin, Sancha, primary, Millan, David, primary, Biankin, Andrew V., primary, and McNeish, Iain A., primary

Published
2023
Full Text
View/download PDF

19. Figure S3 from The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma

Author

Cooke, Susanna L., primary, Ennis, Darren, primary, Evers, Lisa, primary, Dowson, Suzanne, primary, Chan, Mei Yen, primary, Paul, James, primary, Hirschowitz, Lynn, primary, Glasspool, Rosalind M., primary, Singh, Naveena, primary, Bell, Sarah, primary, Day, Elizabeth, primary, Kochman, Agata, primary, Wilkinson, Nafisa, primary, Beer, Philip, primary, Martin, Sancha, primary, Millan, David, primary, Biankin, Andrew V., primary, and McNeish, Iain A., primary

Published
2023
Full Text
View/download PDF

20. Supplementary methods and legends from The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma

Author

Cooke, Susanna L., primary, Ennis, Darren, primary, Evers, Lisa, primary, Dowson, Suzanne, primary, Chan, Mei Yen, primary, Paul, James, primary, Hirschowitz, Lynn, primary, Glasspool, Rosalind M., primary, Singh, Naveena, primary, Bell, Sarah, primary, Day, Elizabeth, primary, Kochman, Agata, primary, Wilkinson, Nafisa, primary, Beer, Philip, primary, Martin, Sancha, primary, Millan, David, primary, Biankin, Andrew V., primary, and McNeish, Iain A., primary

Published
2023
Full Text
View/download PDF

21. CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data

Author

Karamouza, Eleni, primary, Glasspool, Rosalind M., additional, Kelly, Caroline, additional, Lewsley, Liz-Anne, additional, Carty, Karen, additional, Kristensen, Gunnar B., additional, Ethier, Josee-Lyne, additional, Kagimura, Tatsuo, additional, Yanaihara, Nozomu, additional, Cecere, Sabrina Chiara, additional, You, Benoit, additional, Boere, Ingrid A., additional, Pujade-Lauraine, Eric, additional, Ray-Coquard, Isabelle, additional, Proust-Lima, Cécile, additional, and Paoletti, Xavier, additional

Published
2023
Full Text
View/download PDF

22. CA-125 Early Dynamics to Predict Overall Survival in Women with Newly Diagnosed Advanced Ovarian Cancer Based on Meta-Analysis Data

Author

Karamouza, Eleni, Glasspool, Rosalind M., Kelly, Caroline, Lewsley, Liz Anne, Carty, Karen, Kristensen, Gunnar B., Ethier, Josee Lyne, Kagimura, Tatsuo, Yanaihara, Nozomu, Cecere, Sabrina Chiara, You, Benoit, Boere, Ingrid A., Pujade-Lauraine, Eric, Ray-Coquard, Isabelle, Proust-Lima, Cécile, Paoletti, Xavier, Karamouza, Eleni, Glasspool, Rosalind M., Kelly, Caroline, Lewsley, Liz Anne, Carty, Karen, Kristensen, Gunnar B., Ethier, Josee Lyne, Kagimura, Tatsuo, Yanaihara, Nozomu, Cecere, Sabrina Chiara, You, Benoit, Boere, Ingrid A., Pujade-Lauraine, Eric, Ray-Coquard, Isabelle, Proust-Lima, Cécile, and Paoletti, Xavier

Abstract

(1) Background: Cancer antigen 125 (CA-125) is a protein produced by ovarian cancer cells that is used for patients’ monitoring. However, the best ways to analyze its decline and prognostic role are poorly quantified. (2) Methods: We leveraged individual patient data from the Gynecologic Cancer Intergroup (GCIG) meta-analysis (N = 5573) to compare different approaches summarizing the early trajectory of CA-125 before the prediction time (called the landmark time) at 3 or 6 months after treatment initiation in order to predict overall survival. These summaries included observed and estimated measures obtained by a linear mixed model (LMM). Their performances were evaluated by 10-fold cross-validation with the Brier score and the area under the ROC (AUC). (3) Results: The estimated value and the last observed value at 3 months were the best measures used to predict overall survival, with an AUC of 0.75 CI 95% [0.70; 0.80] at 24 and 36 months and 0.74 [0.69; 0.80] and 0.75 [0.69; 0.80] at 48 months, respectively, considering that CA-125 over 6 months did not improve the AUC, with 0.74 [0.68; 0.78] at 24 months and 0.71 [0.65; 0.76] at 36 and 48 months. (4) Conclusions: A 3-month surveillance provided reliable individual information on overall survival until 48 months for patients receiving first-line chemotherapy.

Published
2023

23. Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10

Author

Kristeleit, Rebecca S., primary, Drew, Yvette, additional, Oza, Amit M., additional, Domchek, Susan M., additional, Banerjee, Susana, additional, Glasspool, Rosalind M., additional, Balmaña, Judith, additional, Chen, Lee-may, additional, Patel, Manish R., additional, Burris, Howard A., additional, Safra, Tamar, additional, Borrow, Jennifer, additional, Lin, Kevin K., additional, Goble, Sandra, additional, Maloney, Lara, additional, and Shapira-Frommer, Ronnie, additional

Published
2022
Full Text
View/download PDF

24. Investigating the Impact of Ultra-Radical Surgery on Survival in Advanced Ovarian Cancer Using Population-Based Data in a Multicentre UK Study

Author

Cummins, Carole, primary, Kumar, Satyam, additional, Long, Joanna, additional, Balega, Janos, additional, Broadhead, Tim, additional, Duncan, Timothy, additional, Edmondson, Richard J., additional, Fotopoulou, Christina, additional, Glasspool, Rosalind M., additional, Kolomainen, Desiree, additional, Leeson, Simon, additional, Manchanda, Ranjit, additional, Morrison, Jo, additional, Naik, Raj, additional, Tidy, John A., additional, Wood, Nick, additional, and Sundar, Sudha, additional

Published
2022
Full Text
View/download PDF

25. A Randomised, Multi-centre Phase II Trial of Weekly Paclitaxel and Vistusertib in Platinum-Resistant Ovarian High-Grade Serous Carcinoma: OCTOPUS Arm 1

Author

Banerjee, Susana, primary, Giannone, Gaia, additional, Clamp, Andrew, additional, Glasspool, Rosalind M., additional, Herbertson, Rebecca, additional, Krell, Jonathan, additional, Riisnaes, Ruth, additional, Ennis, Darren P, additional, Mirza, Hasan B, additional, Cheng, Zhao, additional, McDermott, Jacqueline, additional, Green, Clare, additional, Kristeleit, Rebecca, additional, George, Angela, additional, Gourley, Charlie, additional, Lewsley, Liz-Anne, additional, Rai, Debbie, additional, Banerji, Udai, additional, Hinsley, Samantha, additional, and McNeish, Iain A, additional

Published
2022
Full Text
View/download PDF

26. Survival Prognostic and Surrogate Values of the Early Modeled Ca-125 Kelim Score in First-Line Treatment of Ovarian Cancer: Results from The Gcig Individual Patient Data Meta-Analysis

Author

Corbaux, Pauline, primary, You, Benoit, additional, Glasspool, Rosalind M., additional, Yanaihara, Nozomu, additional, Tinker, Anna V., additional, Lindemann, Kristina, additional, Ray-Coquard, Isabelle-Laure, additional, Mirza, Mansoor Raza, additional, Subtil, Fabien, additional, Colomban, Olivier, additional, Péron, Julien, additional, Karamouza, Eleni, additional, McNeish, Iain, additional, Hinsley, Samantha, additional, Kagimura, Tatsuo, additional, Welch, Stephen, additional, Lewsley, Liz-Anne, additional, Paoletti, Xavier, additional, and Cook, Adrian, additional

Published
2022
Full Text
View/download PDF

28. Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” Gynecol. Oncol. 154 (2019) 441–448

Author

Cohen, Paul A., primary, Powell, Aime, additional, Böhm, Steffen, additional, Gilks, C. Blake, additional, Stewart, Colin J.R., additional, Meniawy, Tarek M., additional, Bulsara, Max, additional, Avril, Stefanie, additional, Brockbank, Eleanor C., additional, Bosse, Tjalling, additional, de Azevedo Focchi, Gustavo Rubino, additional, Ganesan, Raji, additional, Glasspool, Rosalind M., additional, Howitt, Brooke E., additional, Kim, Hyun-Soo, additional, Lee, Jung-Yun, additional, Le, Nhu D., additional, Lockley, Michelle, additional, Manchanda, Ranjit, additional, Mandalia, Trupti, additional, McCluggage, W. Glenn, additional, McNeish, Iain, additional, Midha, Divya, additional, Srinivasan, Radhika, additional, Tan, Yun Yi, additional, van der Griend, Rachael, additional, Yunokawa, Mayu, additional, Zannoni, Gian F., additional, and Singh, Naveena, additional

Published
2021
Full Text
View/download PDF

29. Assessment of progression-free survival as a surrogate end point of overall survival in first-line treatment of ovarian cancer

Author

Paoletti, Xavier, Lewsley, Liz-Anne, Daniele, Gennaro, Cook, Adrian, Yanaihara, Nozomu, Tinker, Anna, Kristensen, Gunnar, Ottevanger, Petronella B., Aravantinos, Gerasimos, Miller, Austin, Boere, Ingrid A., Fruscio, Robert, Reyners, Anna K. L., Pujade-Lauraine, Eric, Harkin, Andrea, Pignata, Sandro, Kagimura, Tatsuo, Welch, Stephen, Paul, James, Karamouza, Eleni, and Glasspool, Rosalind M.

Abstract

Importance: The Gynecologic Cancer InterGroup (GCIG) recommended that progression-free survival (PFS) can serve as a primary end point instead of overall survival (OS) in advanced ovarian cancer. Evidence is lacking for the validity of PFS as a surrogate marker of OS in the modern era of different treatment types.\ud \ud Objective: To evaluate whether PFS is a surrogate end point for OS in patients with advanced ovarian cancer.\ud \ud Data Sources: In September 2016, a comprehensive search of publications in MEDLINE was conducted for randomized clinical trials of systematic treatment in patients with newly diagnosed ovarian, fallopian tube, or primary peritoneal cancer. The GCIG groups were also queried for potentially completed but unpublished trials.\ud \ud Study Selection: Studies with a minimum sample size of 60 patients published since 2001 with PFS and OS rates available were eligible. Investigational treatments considered included initial, maintenance, and intensification therapy consisting of agents delivered at a higher dose and/or frequency compared with that in the control arm.\ud \ud Data Extraction and Synthesis: Using the meta-analytic approach on randomized clinical trials published from January 1, 2001, through September 25, 2016, correlations between PFS and OS at the individual level were estimated using the Kendall τ model; between-treatment effects on PFS and OS at the trial level were estimated using the Plackett copula bivariate (R2) model. Criteria for PFS surrogacy required R2 ≥ 0.80 at the trial level. Analysis was performed from January 7 through March 20, 2019.\ud \ud Main Outcomes and Measures: Overall survival and PFS based on measurement of cancer antigen 125 levels confirmed by radiological examination results or by combined GCIG criteria.\ud \ud Results: In this meta-analysis of 17 unique randomized trials of standard (n = 7), intensification (n = 5), and maintenance (n = 5) chemotherapies or targeted treatments with data from 11 029 unique patients (median age, 58 years [range, 18-88 years]), a high correlation was found between PFS and OS at the individual level (τ = 0.724; 95% CI, 0.717-0.732), but a low correlation was found at the trial level (R2 = 0.24; 95% CI, 0-0.59). Subgroup analyses led to similar results. In the external validation, 14 of the 16 hazard ratios for OS in the published reports fell within the 95% prediction interval from PFS.\ud \ud Conclusions and Relevance: This large meta-analysis of individual patient data did not establish PFS as a surrogate end point for OS in first-line treatment of advanced ovarian cancer, but the analysis was limited by the narrow range of treatment effects observed or by poststudy treatment. These results suggest that if PFS is chosen as a primary end point, OS must be measured as a secondary end point.

Published
2020

30. COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA

Author

Macintyre, Geoff, Goranova, Teodora E., De Silva, Dilrini, Ennis, Darren, Piskorz, Anna M., Eldridge, Matthew, Sie, Daoud, Lewsley, Liz-Anne, Hanif, Aishah, Wilson, Cheryl, Dowson, Suzanne, Glasspool, Rosalind M., Lockley, Michelle, Brockbank, Elly, Montes, Ana, Walther, Axel, Sundar, Sudha, Edmondson, Richard, Hall, Geoff D., Clamp, Andrew, Gourley, Charlie, Hall, Marcia, Fotopoulou, Christina, Gabra, Hani, Paul, James, Supernat, Anna, Millan, David, Hoyle, Aoisha, Bryson, Gareth, Nourse, Craig, Mincarelli, Laura, Sanchez, Luis Navarro, Ylstra, Bauke, Jimenez-Linan, Mercedes, Moore, Luiza, Hofmann, Oliver, Markowetz, Florian, McNeish, Iain A., Brenton, James D., Human genetics, CCA - Cancer biology and immunology, and Pathology

Published
2019

32. Corrigendum to “Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data” [Gynecol. Oncol. 154 (2019) 441–448]

Author

Cohen, Paul A., primary, Powell, Aime, additional, Böhm, Steffen, additional, Gilks, C. Blake, additional, Stewart, Colin J.R., additional, Meniawy, Tarek M., additional, Bulsara, Max, additional, Avril, Stefanie, additional, Brockbank, Eleanor C., additional, Bosse, Tjalling, additional, de Azevedo Focchi, Gustavo Rubino, additional, Ganesan, Raji, additional, Glasspool, Rosalind M., additional, Howitt, Brooke E., additional, Kim, Hyun-Soo, additional, Lee, Jung-Yun, additional, Le, Nhu D., additional, Lockley, Michelle, additional, Manchanda, Ranjit, additional, Mandalia, Trupti, additional, McCluggage, W. Glenn, additional, McNeish, Iain, additional, Midha, Divya, additional, Srinivasan, Radhika, additional, Tan, Yun Yi, additional, van der Griend, Rachael, additional, Yunokawa, Mayu, additional, Zannoni, Gian F., additional, and Singh, Naveena, additional

Published
2020
Full Text
View/download PDF

33. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial

Author

Clamp, Andrew R, primary, James, Elizabeth C, additional, McNeish, Iain A, additional, Dean, Andrew, additional, Kim, Jae-Weon, additional, O'Donnell, Dearbhaile M, additional, Hook, Jane, additional, Coyle, Christopher, additional, Blagden, Sarah, additional, Brenton, James D, additional, Naik, Raj, additional, Perren, Tim, additional, Sundar, Sudha, additional, Cook, Adrian D, additional, Gopalakrishnan, Gosala S, additional, Gabra, Hani, additional, Lord, Rosemary, additional, Dark, Graham, additional, Earl, Helena M, additional, Hall, Marcia, additional, Banerjee, Susana, additional, Glasspool, Rosalind M, additional, Jones, Rachel, additional, Williams, Sarah, additional, Swart, Ann Marie, additional, Stenning, Sally, additional, Parmar, Mahesh, additional, Kaplan, Richard, additional, and Ledermann, Jonathan A, additional

Published
2019
Full Text
View/download PDF

34. Abstract AP09: COPY-NUMBER SIGNATURES AND MUTATIONAL PROCESSES IN HIGH GRADE SEROUS OVARIAN CARCINOMA

Author

Macintyre, Geoff, primary, Goranova, Teodora E., additional, Silva, Dilrini De, additional, Ennis, Darren, additional, Piskorz, Anna M., additional, Eldridge, Matthew, additional, Sie, Daoud, additional, Lewsley, Liz-Anne, additional, Hanif, Aishah, additional, Wilson, Cheryl, additional, Dowson, Suzanne, additional, Glasspool, Rosalind M., additional, Lockley, Michelle, additional, Brockbank, Elly, additional, Montes, Ana, additional, Walther, Axel, additional, Sundar, Sudha, additional, Edmondson, Richard, additional, Hall, Geoff D., additional, Clamp, Andrew, additional, Gourley, Charlie, additional, Hall, Marcia, additional, Fotopoulou, Christina, additional, Gabra, Hani, additional, Paul, James, additional, Supernat, Anna, additional, Millan, David, additional, Hoyle, Aoisha, additional, Bryson, Gareth, additional, Nourse, Craig, additional, Mincarelli, Laura, additional, Sanchez, Luis Navarro, additional, Ylstra, Bauke, additional, Jimenez-Linan, Mercedes, additional, Moore, Luiza, additional, Hofmann, Oliver, additional, Markowetz, Florian, additional, McNeish, Iain A., additional, and Brenton, James D., additional

Published
2019
Full Text
View/download PDF

35. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data

Author

Cohen, Paul A., Powell, Aime, Böhm, Steffen, Gilks, C. Blake, Stewart, Colin J.R., Meniawy, Tarek M., Bulsara, Max, Avril, Stefanie, Brockbank, Eleanor C., Bosse, Tjalling, de Azevedo Focchi, Gustavo Rubino, Ganesan, Raji, Glasspool, Rosalind M., Howitt, Brooke E., Kim, Hyun-Soo, Lee, Jung-Yun, Le, Nhu D., Lockley, Michelle, Manchanda, Ranjit, Mandalia, Trupti, McCluggage, W. Glenn, McNeish, Iain, Midha, Divya, Srinivasan, Radhika, Tan, Yun Yi, van der Griend, Rachael, Yunokawa, Mayu, Zannoni, Gian F., Singh, Naveena, Aggarwal, Simi, Bronger, Holger, Brown, Elizabeth B., Buck, Martin, Bukhari, Syed A., Coghlan, Edwina, Cope, Nichola, de Almeida, Michelle Samora, De Kroon, Cornelius D., Dean, Andrew, Devlin, Michael-John, Ditzel, Helena M., Drecoll, Enken, Ebata, Takahiro, Fagotti, Anna, Faruqi, Asma, Feeney, Laura, Gupta, Kavita, Harley, Ian, Inzani, Frediano, Jeyarajah, Arjun R., Koay, M.H. Eleanor, Kroep, Judith R., Leung, Yee, Loft, Alice R., MaGee, Daniel, McKenna, Sarah, Millan, David, Millar, Joanne, Miller, Rowan, Mohan, Ganendra R., Mughal, Sohail, Nicolau, Sergio Mancini, Nevin, James, Oakley, Abigail S., Quigley, Mary, Rai, Bhavana, Rajwanshi, Arvind, Salfinger, Stuart G., Scambia, Giovanni, Scatchard, Kate, Schmalfeldt, Barbara, Simcock, Bryony, Singh, Priya, Strickland, Kyle C., Suri, Vainta, Syed, Sheeba, Sykes, Peter, Tamura, Kenji, Tan, Adeline, Tan, Jason, Thompson, Emily, Tinker, Anna V., Trevisan, Georgia, Uyeda, Maria Gabriela Baumgarten Kuster, Vaughan, Michelle M., Weichert, Wilko, Williams, Anthony, Williams, Sarah, Yoshida, Hiroshi, and Zorzato, Pier Carlo

Abstract

Objective:\ud There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into complete/near-complete (CRS3), partial (CRS2), and no/minimal (CRS1) response after neoadjuvant chemotherapy (NACT). Our aim was to review current evidence to determine whether the CRS is prognostic in women with tubo-ovarian HGSC treated with NACT.\ud \ud Methods:\ud We established an international collaboration to conduct a systematic review and meta-analysis, pooling individual patient data from 16 sites in 11 countries. Patients had stage IIIC/IV HGSC, 3–4 NACT cycles and >6-months follow-up. Random effects models were used to derive combined odds ratios in the pooled population to investigate associations between CRS and progression free and overall survival (PFS and OS).\ud \ud Results:\ud 877 patients were included from published and unpublished studies. Median PFS and OS were 15 months (IQR 5–65) and 28 months (IQR 7–92) respectively. CRS3 was seen in 249 patients (28%). The pooled hazard ratios (HR) for PFS and OS for CRS3 versus CRS1/CRS2 were 0·55 (95% CI, 0·45–0·66; P

Published
2019

36. Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis.

Author

Lee, Chee Khoon, Friedlander, Michael L., Tjokrowidjaja, Angelina, Ledermann, Jonathan A., Coleman, Robert L., Mirza, Mansoor R., Matulonis, Ursula A., Pujade‐Lauraine, Eric, Bloomfield, Ralph, Goble, Sandra, Wang, Ping, Glasspool, Rosalind M., and Scott, Clare L.

Subjects
OVARIAN cancer, PROGRESSION-free survival, GENETIC mutation, FORECASTING, POLY(ADP-ribose) polymerase, BRCA genes, POLYMERASES
Abstract

BACKGROUND: The authors performed a meta‐analysis to better quantify the benefit of maintenance poly(ADP‐ribose) polymerase inhibitor (PARPi) therapy to inform practice in platinum‐sensitive, recurrent, high‐grade ovarian cancer for patient subsets with the following characteristics: germline BRCA mutation (gBRCAm), somatic BRCA mutation (sBRCAm), wild‐type BRCA but homologous recombinant‐deficient (HRD), homologous recombinant‐proficient (HRP), and baseline clinical prognostic characteristics. METHODS: Randomized trials comparing a PARPi versus placebo as maintenance treatment were identified from electronic databases. Treatment estimates of progression‐free survival were pooled across trials using the inverse variance weighted method. RESULTS: Four trials included 972 patients who received a PARPi (olaparib, 31%; niraparib, 35%; or rucaparib, 34%) and 530 patients who received placebo. For patients who had germline BRCA1 mutation (gBRCAm1) (N = 471), the hazard ratio (HR) was 0.29 (95% CI, 0.23‐0.37); for those who had germline BRCA2 mutation (gBRCAm2) (N = 236), the HR was 0.26 (95% CI, 0.17‐0.39); and, for those who had sBRCAm (N = 123), the HR was 0.22 (95% CI, 0.12‐0.41). The treatment effect was similar between the gBRCAm and sBRCAm subsets (P =.48). In patients who had wild‐type BRCA HRD tumors (excluding sBRCAm; N = 309), the HR was 0.41 (95% CI, 0.31‐0.56); and, in those who had wild‐type BRCA HRP tumors (N = 346), the HR was 0.64 (95% CI, 0.49‐0.83). The relative treatment effect was greater for the BRCAm versus HRD (P =.03), BRCAm versus HRP (P <.00001), and HRD versus HRP (P <.00001) subsets. There was no difference in benefit based on age, response after recent chemotherapy, and prior bevacizumab. CONCLUSIONS: In platinum‐sensitive, recurrent, high‐grade ovarian cancer, maintenance PARPi improves progression‐free survival for all patient subsets. PARPi therapy has a similar magnitude of benefit for sBRCAm and gBRCAm. Although patients with BRCAm derive the greatest benefit, the absence of a BRCAm or HRD could not be used to exclude patients from maintenance PARPi therapy. BRCA mutation status is able to predict for the magnitude of PARP inhibitor benefit in platinum‐sensitive recurrent high‐grade ovarian tumor. However, the absence of a BRCA mutation or homologous recombinant deficiency in high‐grade ovarian tumor cannot be used to exclude patients from such therapy. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

37. Safety and utility of image-guided research\ud biopsies in relapsed high-grade serous\ud ovarian carcinoma—experience of the\ud BriTROC consortium

Author

Goranova, Teodora, Ennis, Darren, Piskorz, Anna M., Macintyre, Geoff, Lewsley, Liz-Anne, Stobo, Jon, Wilson, Cheryl, Kay, David, Glasspool, Rosalind M., Lockley, Michelle, Brockbank, Eleanor, Montes, Ana, Walther, Axel, Sundar, Sudha, Edmondson, Richard, Hall, Geoff D., Clamp, Andrew, Gourley, Charles, Hall, Marcia, Fotopoulou, Christina, Gabra, Hani, Freeman, Susan, Moore, Luisa, Jimenez-Linan, Mercedes, Paul, Jim, Brenton, James D., and McNeish, Iain A.

Abstract

Background: Investigating tumour evolution and acquired chemotherapy resistance requires analysis of sequential tumour\ud material. We describe the feasibility of obtaining research biopsies in women with relapsed ovarian high-grade serous carcinoma\ud (HGSC).\ud Methods: Women with relapsed ovarian HGSC underwent either image-guided biopsy or intra-operative biopsy during\ud secondary debulking, and samples were fixed in methanol-based fixative. Tagged-amplicon sequencing was performed on biopsy\ud DNA.\ud Results: We screened 519 patients in order to enrol 220. Two hundred and two patients underwent successful biopsy, 118 of which\ud were image-guided. There were 22 study-related adverse events (AE) in the image-guided biopsies, all grades 1 and 2; pain was\ud the commonest AE. There were pre-specified significant AE in 3/118 biopsies (2.5%). 87% biopsies were fit-for-purpose for\ud genomic analyses. Median DNA yield was 2.87 mg, and was higher in biopsies utilising 14 G or 16 G needles compared to 18 G.\ud TP53 mutations were identified in 94.4% patients.\ud Conclusions: Obtaining tumour biopsies for research in relapsed HGSC is safe and feasible. Adverse events are rare. The large\ud majority of biopsies yield sufficient DNA for genomic analyses—we recommend use of larger gauge needles and methanol\ud fixation for such biopsies, as DNA yields are higher but with no increase in AEs.

Published
2017

38. Pathological Chemotherapy Response Score Predicts Survival in Patients with Advanced Ovarian Cancer Receiving Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis of Individual Patient Data

Author

Cohen, Paul, primary, Powell, Aime, additional, Böhm, Steffen, additional, Gilks, C. Blake, additional, Stewart, Colin J.R., additional, Meniawy, Tarek M., additional, Bulsara, Max, additional, Avril, Stefanie, additional, Brockbank, Elly C., additional, Bosse, Tjalling, additional, Focchi, Gustavo Rubino de Azevedo, additional, Ganesan, Raji, additional, Glasspool, Rosalind M., additional, Howitt, Brooke E., additional, Kim, Hyun-Soo, additional, Lee, Jung-Yun, additional, Lee, Nhu D., additional, Lockley, Michelle, additional, Manchanda, Ranchit, additional, Mandalia, Trupti, additional, McCluggage, W. Glenn, additional, McNeish, Iain, additional, Midha, Divya, additional, Srinivasan, Radhika, additional, Tan, Yun Yi, additional, van der Griend, Rachael, additional, Yunokawa, Mayu, additional, Zannoni, Gian F., additional, Network, HGSC CRS Collaborative, additional, and Singh, Naveena, additional

Published
2018
Full Text
View/download PDF

39. The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma

Author

Cooke, Susanna L., primary, Ennis, Darren, additional, Evers, Lisa, additional, Dowson, Suzanne, additional, Chan, Mei Yen, additional, Paul, James, additional, Hirschowitz, Lynn, additional, Glasspool, Rosalind M., additional, Singh, Naveena, additional, Bell, Sarah, additional, Day, Elizabeth, additional, Kochman, Agata, additional, Wilkinson, Nafisa, additional, Beer, Philip, additional, Martin, Sancha, additional, Millan, David, additional, Biankin, Andrew V., additional, and McNeish, Iain A., additional

Published
2017
Full Text
View/download PDF

40. Copy-number signatures and mutational processes in ovarian carcinoma

Author

Macintyre, Geoff, primary, Goranova, Teodora E., additional, De Silva, Dilrini, additional, Ennis, Darren, additional, Piskorz, Anna M., additional, Eldridge, Matthew, additional, Sie, Daoud, additional, Lewsley, Liz-Anne, additional, Hanif, Aishah, additional, Wilson, Cheryl, additional, Dowson, Suzanne, additional, Glasspool, Rosalind M., additional, Lockley, Michelle, additional, Brockbank, Elly, additional, Montes, Ana, additional, Walther, Axel, additional, Sundar, Sudha, additional, Edmondson, Richard, additional, Hall, Geoff D., additional, Clamp, Andrew, additional, Gourley, Charlie, additional, Hall, Marcia, additional, Fotopoulou, Christina, additional, Gabra, Hani, additional, Paul, James, additional, Supernat, Anna, additional, Millan, David, additional, Hoyle, Aoisha, additional, Bryson, Gareth, additional, Nourse, Craig, additional, Mincarelli, Laura, additional, Sanchez, Luis Navarro, additional, Ylstra, Bauke, additional, Jimenez-Linan, Mercedes, additional, Moore, Luiza, additional, Hofmann, Oliver, additional, Markowetz, Florian, additional, McNeish, Iain A., additional, and Brenton, James D., additional

Published
2017
Full Text
View/download PDF

41. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer

Author

Hampras, Shalaka S, Sucheston-Campbell, Lara E, Cannioto, Rikki, Chang-Claude, Jenny, Modugno, Francesmary, Doerk, Thilo, Hillemanns, Peter, Preus, Leah, Knutson, Keith L, Wallace, Paul K, Hong, Chi-chen, Friel, Grace, Davis, Warren, Nesline, Mary, Pearce, Celeste L, Kelemen, Linda E, Goodman, Marc T, Bandera, Elisa V, Terry, Kathryn L, Schoof, Nils, Eng, Kevin H, Clay, Alyssa I, Singh, Prashant K, Joseph, Janine M, Aben, Katja K H, Anton-Culver, Hoda, Antonenkova, Natalia, Baker, Helen, Bean, Yukie, Beckmann, Matthias W, Bisogna, Maria, Bjorge, Line, Bogdanova, Natalia, Brinton, Louise A, Brooks-Wilson, Angela, Bruinsma, Fiona, Butzow, Ralf, Campbell, Ian G, Carty, Karen, Cook, Linda S, Cramer, Daniel W, Cybulski, Cezary, Dansonka-Mieszkowska, Agnieszka, Dennis, Joe, Despierre, Evelyn, Dicks, Ed, Doherty, Jennifer A, Du Bois, Andreas, Durst, Matthias, Easton, Doug, Eccles, Diana, Edwards, Robert P, Ekici, Arif B, Fasching, Peter A, Fridley, Brooke L, Gao, Yu-Tang, Gentry-Maharaj, Aleksandra, Giles, Graham, Glasspool, Rosalind M, Gronwald, Jacek, Harrington, Patricia, Harter, Philipp, Hasmad, Hanis Nazihah, Hein, Alexander, Heitz, Florian, Hildebrandt, Michelle A T, Hogdall, Claus, Hogdall, Estrid, Hosono, Satoyo, Iversen, Edwin S, Jakubowska, Anna, Jensen, Allan, Ji, Bu-Tian, Karlan, Beth Y, Kellar, Melissa, Kelley, Joseph L, Kiemeney, Lambertus A, Klapdor, Rüdiger, Kolomeyevskaya, Nonna, Krakstad, Camilla, Kjaer, Susanne K, Kruszka, Bridget, Kupryjanczyk, Jolanta, Lambrechts, Diether, Lambrechts, Sandrina, Le, Nhu D, Lee, Alice W, Lele, Shashikant, Leminen, Arto, Lester, Jenny, Levine, Douglas A, Liang, Dong, Lissowska, Jolanta, Liu, Song, Lu, Karen, Lubinski, Jan, Lundvall, Lene, Massuger, Leon F A G, Matsuo, Keitaro, McGuire, Valeria, McLaughlin, John R, McNeish, Ian, Menon, Usha, Moes-Sosnowska, Joanna, Narod, Steven A, Nedergaard, Lotte, Nevanlinna, Heli, Nickels, Stefan, Olson, Sara H, Orlow, Irene, Weber, Rachel Palmieri, Paul, James, Pejovic, Tanja, Pelttari, Liisa M, Perkins, Barbara, Permuth-Wey, Jenny, Pike, Malcolm C, Plisiecka-Halasa, Joanna, Poole, Elizabeth M, Risch, Harvey A, Rossing, Mary Anne, Rothstein, Joseph H, Rudolph, Anja, Runnebaum, Ingo B, Rzepecka, Iwona K, Salvesen, Helga B, Schernhammer, Eva, Schmitt, Kristina, Schwaab, Ira, Shu, Xiao-Ou, Shvetsov, Yurii B, Siddiqui, Nadeem, Sieh, Weiva, Song, Honglin, Southey, Melissa C, Tangen, Ingvild L, Teo, Soo-Hwang, Thompson, Pamela J, Timorek, Agnieszka, Tsai, Ya-Yu, Tworoger, Shelley S, Tyrer, Jonathan, van Altena, Anna M, Vergote, Ignace, Vierkant, Robert A, Walsh, Christine, Wang-Gohrke, Shan, Wentzensen, Nicolas, Whittemore, Alice S, Wicklund, Kristine G, Wilkens, Lynne R, Wu, Anna H, Wu, Xifeng, Woo, Yin Ling, Yang, Hannah, Zheng, Wei, Ziogas, Argyrios, Gayther, Simon A, Ramus, Susan J, Sellers, Thomas A, Schildkraut, Joellen M, Phelan, Catherine M, Berchuck, Andrew, Chenevix-Trench, Georgia, Cunningham, Julie M, Pharoah, Paul, Ness, Roberta B, Odunsi, Kunle, Goode, Ellen L, Moysich, Kirsten B, Hampras, Shalaka S, Sucheston-Campbell, Lara E, Cannioto, Rikki, Chang-Claude, Jenny, Modugno, Francesmary, Doerk, Thilo, Hillemanns, Peter, Preus, Leah, Knutson, Keith L, Wallace, Paul K, Hong, Chi-chen, Friel, Grace, Davis, Warren, Nesline, Mary, Pearce, Celeste L, Kelemen, Linda E, Goodman, Marc T, Bandera, Elisa V, Terry, Kathryn L, Schoof, Nils, Eng, Kevin H, Clay, Alyssa I, Singh, Prashant K, Joseph, Janine M, Aben, Katja K H, Anton-Culver, Hoda, Antonenkova, Natalia, Baker, Helen, Bean, Yukie, Beckmann, Matthias W, Bisogna, Maria, Bjorge, Line, Bogdanova, Natalia, Brinton, Louise A, Brooks-Wilson, Angela, Bruinsma, Fiona, Butzow, Ralf, Campbell, Ian G, Carty, Karen, Cook, Linda S, Cramer, Daniel W, Cybulski, Cezary, Dansonka-Mieszkowska, Agnieszka, Dennis, Joe, Despierre, Evelyn, Dicks, Ed, Doherty, Jennifer A, Du Bois, Andreas, Durst, Matthias, Easton, Doug, Eccles, Diana, Edwards, Robert P, Ekici, Arif B, Fasching, Peter A, Fridley, Brooke L, Gao, Yu-Tang, Gentry-Maharaj, Aleksandra, Giles, Graham, Glasspool, Rosalind M, Gronwald, Jacek, Harrington, Patricia, Harter, Philipp, Hasmad, Hanis Nazihah, Hein, Alexander, Heitz, Florian, Hildebrandt, Michelle A T, Hogdall, Claus, Hogdall, Estrid, Hosono, Satoyo, Iversen, Edwin S, Jakubowska, Anna, Jensen, Allan, Ji, Bu-Tian, Karlan, Beth Y, Kellar, Melissa, Kelley, Joseph L, Kiemeney, Lambertus A, Klapdor, Rüdiger, Kolomeyevskaya, Nonna, Krakstad, Camilla, Kjaer, Susanne K, Kruszka, Bridget, Kupryjanczyk, Jolanta, Lambrechts, Diether, Lambrechts, Sandrina, Le, Nhu D, Lee, Alice W, Lele, Shashikant, Leminen, Arto, Lester, Jenny, Levine, Douglas A, Liang, Dong, Lissowska, Jolanta, Liu, Song, Lu, Karen, Lubinski, Jan, Lundvall, Lene, Massuger, Leon F A G, Matsuo, Keitaro, McGuire, Valeria, McLaughlin, John R, McNeish, Ian, Menon, Usha, Moes-Sosnowska, Joanna, Narod, Steven A, Nedergaard, Lotte, Nevanlinna, Heli, Nickels, Stefan, Olson, Sara H, Orlow, Irene, Weber, Rachel Palmieri, Paul, James, Pejovic, Tanja, Pelttari, Liisa M, Perkins, Barbara, Permuth-Wey, Jenny, Pike, Malcolm C, Plisiecka-Halasa, Joanna, Poole, Elizabeth M, Risch, Harvey A, Rossing, Mary Anne, Rothstein, Joseph H, Rudolph, Anja, Runnebaum, Ingo B, Rzepecka, Iwona K, Salvesen, Helga B, Schernhammer, Eva, Schmitt, Kristina, Schwaab, Ira, Shu, Xiao-Ou, Shvetsov, Yurii B, Siddiqui, Nadeem, Sieh, Weiva, Song, Honglin, Southey, Melissa C, Tangen, Ingvild L, Teo, Soo-Hwang, Thompson, Pamela J, Timorek, Agnieszka, Tsai, Ya-Yu, Tworoger, Shelley S, Tyrer, Jonathan, van Altena, Anna M, Vergote, Ignace, Vierkant, Robert A, Walsh, Christine, Wang-Gohrke, Shan, Wentzensen, Nicolas, Whittemore, Alice S, Wicklund, Kristine G, Wilkens, Lynne R, Wu, Anna H, Wu, Xifeng, Woo, Yin Ling, Yang, Hannah, Zheng, Wei, Ziogas, Argyrios, Gayther, Simon A, Ramus, Susan J, Sellers, Thomas A, Schildkraut, Joellen M, Phelan, Catherine M, Berchuck, Andrew, Chenevix-Trench, Georgia, Cunningham, Julie M, Pharoah, Paul, Ness, Roberta B, Odunsi, Kunle, Goode, Ellen L, and Moysich, Kirsten B

Abstract

BACKGROUND: Regulatory T (Treg) cells, a subset of CD4+ T lymphocytes, are mediators of immunosuppression in cancer, and, thus, variants in genes encoding Treg cell immune molecules could be associated with ovarian cancer.METHODS: In a population of 15,596 epithelial ovarian cancer (EOC) cases and 23,236 controls, we measured genetic associations of 1,351 SNPs in Treg cell pathway genes with odds of ovarian cancer and tested pathway and gene-level associations, overall and by histotype, for the 25 genes, using the admixture likelihood (AML) method. The most significant single SNP associations were tested for correlation with expression levels in 44 ovarian cancer patients.RESULTS: The most significant global associations for all genes in the pathway were seen in endometrioid ( p = 0.082) and clear cell ( p = 0.083), with the most significant gene level association seen with TGFBR2 ( p = 0.001) and clear cell EOC. Gene associations with histotypes at p < 0.05 included: IL12 ( p = 0.005 and p = 0.008, serous and high-grade serous, respectively), IL8RA ( p = 0.035, endometrioid and mucinous), LGALS1 ( p = 0.03, mucinous), STAT5B ( p = 0.022, clear cell), TGFBR1 ( p = 0.021 endometrioid) and TGFBR2 ( p = 0.017 and p = 0.025, endometrioid and mucinous, respectively).CONCLUSIONS: Common inherited gene variation in Treg cell pathways shows some evidence of germline genetic contribution to odds of EOC that varies by histologic subtype and may be associated with mRNA expression of immune-complex receptor in EOC patients.

Published
2016

42. Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC)

Author

Jim, Heather S L, Lin, Hui-Yi, Tyrer, Jonathan P, Lawrenson, Kate, Dennis, Joe, Chornokur, Ganna, Chen, Zhihua, Chen, Y Ann, Permuth-Wey, Jennifer, Aben, Katja Kh, Anton-Culver, Hoda, Antonenkova, Natalia, Bruinsma, Fiona, Bandera, Elisa V, Bean, Yukie T, Beckmann, Matthias W, Bisogna, Maria, Bjorge, Line, Bogdanova, Natalia, Brinton, Louise A, Brooks-Wilson, Angela, Bunker, Clareann H, Butzow, Ralf, Campbell, Ian G, Carty, Karen, Chang-Claude, Jenny, Cook, Linda S, Cramer, Daniel W, Cunningham, Julie M, Cybulski, Cezary, Dansonka-Mieszkowska, Agnieszka, Du Bois, Andreas, Despierre, Evelyn, Sieh, Weiva, Doherty, Jennifer A, Doerk, Thilo, Durst, Matthias, Easton, Douglas F, Eccles, Diana M, Edwards, Robert P, Ekici, Arif B, Fasching, Peter A, Fridley, Brooke L, Gao, Yu-Tang, Gentry-Maharaj, Aleksandra, Giles, Graham, Glasspool, Rosalind M, Goodman, Marc T, Gronwald, Jacek, Harter, Philipp, Hasmad, Hanis N., Hein, Alexander, Heitz, Florian, Hildebrandt, Michelle A T, Hillemanns, Peter, Hogdall, Claus K, Hogdall, Estrid, Hosono, Satoyo, Iversen, Edwin S, Jakubowska, Anna, Jensen, Allan, Ji, Bu-Tian, Karlan, Beth Y, Kellar, Melissa, Kiemeney, Lambertus A, Krakstad, Camilla, Kjaer, Susanne K, Kupryjanczyk, Jolanta, Vierkant, Robert A, Lambrechts, Diether, Lambrechts, Sandrina, Le, Nhu D, Lee, Alice W, Lele, Shashi, Leminen, Arto, Lester, Jenny, Levine, Douglas A, Liang, Dong, Lim, Boon Kiong, Lissowska, Jolanta, Lu, Karen, Lubinski, Jan, Lundvall, Lene, Massuger, Leon F A G, Matsuo, Keitaro, McGuire, Valerie, McLaughlin, John R, McNeish, Ian, Menon, Usha, Milne, Roger L, Modugno, Francesmary, Thomsen, Lotte, Moysich, Kirsten B, Ness, Roberta B, Nevanlinna, Heli, Eilber, Ursula, Odunsi, Kunle, Olson, Sara H, Orlow, Irene, Orsulic, Sandra, Palmieri Weber, Rachel, Paul, James, Pearce, Celeste L, Pejovic, Tanja, Pelttari, Liisa M, Pike, Malcolm C, Poole, Elizabeth M, Schernhammer, Eva, Risch, Harvey A, Rosen, Barry, Rossing, Mary Anne, Rothstein, Joseph H, Rudolph, Anja, Runnebaum, Ingo B, Rzepecka, Iwona K, Salvesen, Helga B, Schwaab, Ira, Shu, Xiao-Ou, Shvetsov, Yurii B, Siddiqui, Nadeem, Song, Honglin, Southey, Melissa C, Spiewankiewicz, Beata, Sucheston-Campbell, Lara, Teo, Soo-Hwang, Terry, Kathryn L, Thompson, Pamela J, Tangen, Ingvild L, Tworoger, Shelley S, van Altena, Anne M, Vergote, Ignace, Walsh, Christine S, Wang-Gohrke, Shan, Wentzensen, Nicolas, Whittemore, Alice S, Wicklund, Kristine G, Wilkens, Lynne R, Wu, Anna H, Wu, Xifeng, Woo, Yin Ling, Yang, Hannah, Zheng, Wei, Ziogas, Argyrios, Amankwah, Ernest K, Berchuck, Andrew, Schildkraut, Joellen M, Kelemen, Linda E, Ramus, Susan J, Monteiro, Alvaro N A, Goode, Ellen L, Narod, Steven A, Gayther, Simon A, Pharoah, Paul P D, Sellers, Thomas A, Phelan, Catherine M, Jim, Heather S L, Lin, Hui-Yi, Tyrer, Jonathan P, Lawrenson, Kate, Dennis, Joe, Chornokur, Ganna, Chen, Zhihua, Chen, Y Ann, Permuth-Wey, Jennifer, Aben, Katja Kh, Anton-Culver, Hoda, Antonenkova, Natalia, Bruinsma, Fiona, Bandera, Elisa V, Bean, Yukie T, Beckmann, Matthias W, Bisogna, Maria, Bjorge, Line, Bogdanova, Natalia, Brinton, Louise A, Brooks-Wilson, Angela, Bunker, Clareann H, Butzow, Ralf, Campbell, Ian G, Carty, Karen, Chang-Claude, Jenny, Cook, Linda S, Cramer, Daniel W, Cunningham, Julie M, Cybulski, Cezary, Dansonka-Mieszkowska, Agnieszka, Du Bois, Andreas, Despierre, Evelyn, Sieh, Weiva, Doherty, Jennifer A, Doerk, Thilo, Durst, Matthias, Easton, Douglas F, Eccles, Diana M, Edwards, Robert P, Ekici, Arif B, Fasching, Peter A, Fridley, Brooke L, Gao, Yu-Tang, Gentry-Maharaj, Aleksandra, Giles, Graham, Glasspool, Rosalind M, Goodman, Marc T, Gronwald, Jacek, Harter, Philipp, Hasmad, Hanis N., Hein, Alexander, Heitz, Florian, Hildebrandt, Michelle A T, Hillemanns, Peter, Hogdall, Claus K, Hogdall, Estrid, Hosono, Satoyo, Iversen, Edwin S, Jakubowska, Anna, Jensen, Allan, Ji, Bu-Tian, Karlan, Beth Y, Kellar, Melissa, Kiemeney, Lambertus A, Krakstad, Camilla, Kjaer, Susanne K, Kupryjanczyk, Jolanta, Vierkant, Robert A, Lambrechts, Diether, Lambrechts, Sandrina, Le, Nhu D, Lee, Alice W, Lele, Shashi, Leminen, Arto, Lester, Jenny, Levine, Douglas A, Liang, Dong, Lim, Boon Kiong, Lissowska, Jolanta, Lu, Karen, Lubinski, Jan, Lundvall, Lene, Massuger, Leon F A G, Matsuo, Keitaro, McGuire, Valerie, McLaughlin, John R, McNeish, Ian, Menon, Usha, Milne, Roger L, Modugno, Francesmary, Thomsen, Lotte, Moysich, Kirsten B, Ness, Roberta B, Nevanlinna, Heli, Eilber, Ursula, Odunsi, Kunle, Olson, Sara H, Orlow, Irene, Orsulic, Sandra, Palmieri Weber, Rachel, Paul, James, Pearce, Celeste L, Pejovic, Tanja, Pelttari, Liisa M, Pike, Malcolm C, Poole, Elizabeth M, Schernhammer, Eva, Risch, Harvey A, Rosen, Barry, Rossing, Mary Anne, Rothstein, Joseph H, Rudolph, Anja, Runnebaum, Ingo B, Rzepecka, Iwona K, Salvesen, Helga B, Schwaab, Ira, Shu, Xiao-Ou, Shvetsov, Yurii B, Siddiqui, Nadeem, Song, Honglin, Southey, Melissa C, Spiewankiewicz, Beata, Sucheston-Campbell, Lara, Teo, Soo-Hwang, Terry, Kathryn L, Thompson, Pamela J, Tangen, Ingvild L, Tworoger, Shelley S, van Altena, Anne M, Vergote, Ignace, Walsh, Christine S, Wang-Gohrke, Shan, Wentzensen, Nicolas, Whittemore, Alice S, Wicklund, Kristine G, Wilkens, Lynne R, Wu, Anna H, Wu, Xifeng, Woo, Yin Ling, Yang, Hannah, Zheng, Wei, Ziogas, Argyrios, Amankwah, Ernest K, Berchuck, Andrew, Schildkraut, Joellen M, Kelemen, Linda E, Ramus, Susan J, Monteiro, Alvaro N A, Goode, Ellen L, Narod, Steven A, Gayther, Simon A, Pharoah, Paul P D, Sellers, Thomas A, and Phelan, Catherine M

Abstract

Disruption in circadian gene expression, whether due to genetic variation or environmental factors (e.g., light at night, shiftwork), is associated with increased incidence of breast, prostate, gastrointestinal and hematologic cancers and gliomas. Circadian genes are highly expressed in the ovaries where they regulate ovulation; circadian disruption is associated with several ovarian cancer risk factors (e.g., endometriosis). However, no studies have examined variation in germline circadian genes as predictors of ovarian cancer risk and invasiveness. The goal of the current study was to examine single nucleotide polymorphisms (SNPs) in circadian genes BMAL1, CRY2, CSNK1E, NPAS2, PER3, REV1 and TIMELESS and downstream transcription factors KLF10 and SENP3 as predictors of risk of epithelial ovarian cancer (EOC) and histopathologic subtypes. The study included a test set of 3,761 EOC cases and 2,722 controls and a validation set of 44,308 samples including 18,174 (10,316 serous) cases and 26,134 controls from 43 studies participating in the Ovarian Cancer Association Consortium (OCAC). Analysis of genotype data from 36 genotyped SNPs and 4600 imputed SNPs indicated that the most significant association was rs117104877 in BMAL1 (OR = 0.79, 95% CI = 0.68-0.90, p = 5.59 × 10(-4)]. Functional analysis revealed a significant down regulation of BMAL1 expression following cMYC overexpression and increasing transformation in ovarian surface epithelial (OSE) cells as well as alternative splicing of BMAL1 exons in ovarian and granulosa cells. These results suggest that variation in circadian genes, and specifically BMAL1, may be associated with risk of ovarian cancer, likely through disruption of hormonal pathways.

Published
2016

43. No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival

Author

Sucheston-Campbell, Lara E., primary, Cannioto, Rikki, additional, Clay, Alyssa I., additional, Etter, John Lewis, additional, Eng, Kevin H., additional, Liu, Song, additional, Battaglia, Sebastiano, additional, Hu, Qiang, additional, Szender, J. Brian, additional, Minlikeeva, Albina, additional, Joseph, Janine M., additional, Mayor, Paul, additional, Abrams, Scott I., additional, Segal, Brahm H., additional, Wallace, Paul K., additional, Soh, Kah Teong, additional, Zsiros, Emese, additional, Anton-Culver, Hoda, additional, Bandera, Elisa V., additional, Beckmann, Matthias W., additional, Berchuck, Andrew, additional, Bjorge, Line, additional, Bruegl, Amanda, additional, Campbell, Ian G., additional, Campbell, Shawn Patrice, additional, Chenevix-Trench, Georgia, additional, Cramer, Daniel W., additional, Dansonka-Mieszkowska, Agnieszka, additional, Dao, Fanny, additional, Diergaarde, Brenda, additional, Doerk, Thilo, additional, Doherty, Jennifer A., additional, du Bois, Andreas, additional, Eccles, Diana, additional, Engelholm, Svend Aage, additional, Fasching, Peter A., additional, Gayther, Simon A., additional, Gentry-Maharaj, Aleksandra, additional, Glasspool, Rosalind M., additional, Goodman, Marc T., additional, Gronwald, Jacek, additional, Harter, Philipp, additional, Hein, Alexander, additional, Heitz, Florian, additional, Hillemmanns, Peter, additional, Høgdall, Claus, additional, Høgdall, Estrid V.S., additional, Huzarski, Tomasz, additional, Jensen, Allan, additional, Johnatty, Sharon E., additional, Jung, Audrey, additional, Karlan, Beth Y., additional, Klapdor, Reudiger, additional, Kluz, Tomasz, additional, Konopka, Bożena, additional, Kjær, Susanne Krüger, additional, Kupryjanczyk, Jolanta, additional, Lambrechts, Diether, additional, Lester, Jenny, additional, Lubiński, Jan, additional, Levine, Douglas A., additional, Lundvall, Lene, additional, McGuire, Valerie, additional, McNeish, Iain A., additional, Menon, Usha, additional, Modugno, Francesmary, additional, Ness, Roberta B., additional, Orsulic, Sandra, additional, Paul, James, additional, Pearce, Celeste Leigh, additional, Pejovic, Tanja, additional, Pharoah, Paul, additional, Ramus, Susan J., additional, Rothstein, Joseph, additional, Rossing, Mary Anne, additional, Rübner, Matthias, additional, Schildkraut, Joellen M., additional, Schmalfeldt, Barbara, additional, Schwaab, Ira, additional, Siddiqui, Nadeem, additional, Sieh, Weiva, additional, Sobiczewski, Piotr, additional, Song, Honglin, additional, Terry, Kathryn L., additional, Van Nieuwenhuysen, Els, additional, Vanderstichele, Adriaan, additional, Vergote, Ignace, additional, Walsh, Christine S., additional, Webb, Penelope M., additional, Wentzensen, Nicolas, additional, Whittemore, Alice S., additional, Wu, Anna H., additional, Ziogas, Argyrios, additional, Odunsi, Kunle, additional, Chang-Claude, Jenny, additional, Goode, Ellen L., additional, and Moysich, Kirsten B., additional

Published
2016
Full Text
View/download PDF

44. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Squamous Cell Carcinoma of the Ovary

Author

Glasspool, Rosalind M., Martin, Antonio Gonzalez, Millan, David, Lorusso, Domenica, Avall-Lundqvist, Elisabeth, Hurteau, Jean A., Davis, Alison, Hilpert, Felix, Kim, Jae-Weon, Alexandre, Jerome, Ledermann, Jonathan A., Glasspool, Rosalind M., Martin, Antonio Gonzalez, Millan, David, Lorusso, Domenica, Avall-Lundqvist, Elisabeth, Hurteau, Jean A., Davis, Alison, Hilpert, Felix, Kim, Jae-Weon, Alexandre, Jerome, and Ledermann, Jonathan A.

Published
2014

45. Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary.

Author

Glasspool, Rosalind M, González Martín, Antonio, Millan, David, Lorusso, Domenica, Åvall-Lundqvist, Elisabeth, Hurteau, Jean A, Davis, Alison, Hilpert, Felix, Kim, Jae-Weon, Alexandre, Jérôme, Ledermann, Jonathan A, Glasspool, Rosalind M, González Martín, Antonio, Millan, David, Lorusso, Domenica, Åvall-Lundqvist, Elisabeth, Hurteau, Jean A, Davis, Alison, Hilpert, Felix, Kim, Jae-Weon, Alexandre, Jérôme, and Ledermann, Jonathan A

Abstract

Squamous cell carcinoma of the ovary is a rare complication of mature cystic teratoma. The epidemiology, pathology, diagnosis, and management of this rare tumor are reviewed. Clinical characteristics, preoperative imaging, and tumor markers may help to predict malignancy preoperatively. Complete cytoreduction should be the aim of surgery. The prognosis for stage 1A disease is good, but for women with advanced or recurrent disease, it is very poor and has not improved in recent years. At present, there are insufficient data to provide clear guidance on the optimal management strategy for advanced disease, and there is a need to gain an understanding of the biology and to develop novel effective therapies. This will require coordinated international collaboration.

Published
2014
Full Text
View/download PDF

46. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian and Primary Peritoneal Low-Grade Serous Carcinomas

Author

Gourley, Charlie, primary, Farley, John, additional, Provencher, Diane M., additional, Pignata, Sandro, additional, Mileshkin, Linda, additional, Harter, Philipp, additional, Maenpaa, Johanna, additional, Kim, Jae-Weon, additional, Pujaide-Lauraine, Eric, additional, Glasspool, Rosalind M., additional, Ray-Coquard, Isabelle, additional, and Gershenson, David, additional

Published
2014
Full Text
View/download PDF

47. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix

Author

Hasegawa, Kosei, primary, Nagao, Shoji, additional, Yasuda, Masanori, additional, Millan, David, additional, Viswanathan, Akila N., additional, Glasspool, Rosalind M., additional, Devouassoux-Shisheboran, Mojgan, additional, Covens, Alan, additional, Lorusso, Domenica, additional, Kurzeder, Christian, additional, Kim, Jae-Weon, additional, Gladieff, Laurence, additional, Bryce, Jane, additional, Friedlander, Michael, additional, and Fujiwara, Keiichi, additional

Published
2014
Full Text
View/download PDF

49. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Uterine Serous Carcinoma

Author

Sagae, Satoru, primary, Susumu, Nobuyuki, additional, Viswanathan, Akila N., additional, Aoki, Daisuke, additional, Backes, Floor J., additional, Provencher, Diane M., additional, Vaughan, Michelle, additional, Creutzberg, Carien L., additional, Kurzeder, Christian, additional, Kristensen, Gunnar, additional, Lee, Chulmin, additional, Kurtz, Jean-Emmanuel, additional, Glasspool, Rosalind M., additional, and Small, William, additional

Published
2014
Full Text
View/download PDF

50. Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Ovary

Author

Okamoto, Aikou, primary, Glasspool, Rosalind M., additional, Mabuchi, Seiji, additional, Matsumura, Noriomi, additional, Nomura, Hiroyuki, additional, Itamochi, Hiroaki, additional, Takano, Masashi, additional, Takano, Tadao, additional, Susumu, Nobuyuki, additional, Aoki, Daisuke, additional, Konishi, Ikuo, additional, Covens, Alan, additional, Ledermann, Jonathan, additional, Mezzazanica, Delia, additional, Steer, Christopher, additional, Millan, David, additional, McNeish, Iain A., additional, Pfisterer, Jacobus, additional, Kang, Sokbom, additional, Gladieff, Laurence, additional, Bryce, Jane, additional, and Oza, Amit, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results